Intra-Cellular Therapies (NASDAQ: ITCI) to Resume Trading at 7:30 a.m. Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot FDA News Trading Halts

Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA SecuritiesApril 17, 2024 5:13 AM Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501April 16, 2024 7:01 AM Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderApril 16, 2024 7:00 AM Intra-Cellular Therapies (ITCI) Halted, News PendingApril 16, 2024 6:55 AM